L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results

William J. Burke; Anthony E. Ranno; W. H. Roccaforte; Steven P. Wengel; Barbara L. Bayer; Nancy K. Willcockson

doi:10.1111/j.1532-5415.1993.tb06942.x

L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results

William J. Burke, Anthony E. Ranno, W. H. Roccaforte, Steven P. Wengel, Barbara L. Bayer, Nancy K. Willcockson

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Objective: To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion: L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT. 1993 The American Geriatrics Society

Original language	English (US)
Pages (from-to)	367-370
Number of pages	4
Journal	Journal of the American Geriatrics Society
Volume	41
Issue number	4
DOIs	https://doi.org/10.1111/j.1532-5415.1993.tb06942.x
State	Published - Apr 1993

ASJC Scopus subject areas

Geriatrics and Gerontology

Access to Document

10.1111/j.1532-5415.1993.tb06942.x

Cite this

@article{a8483cb4775d4fa39d36067e014715a6,

title = "L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results",

abstract = "Objective: To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion: L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT. 1993 The American Geriatrics Society",

author = "Burke, {William J.} and Ranno, {Anthony E.} and Roccaforte, {W. H.} and Wengel, {Steven P.} and Bayer, {Barbara L.} and Willcockson, {Nancy K.}",

year = "1993",

month = apr,

doi = "10.1111/j.1532-5415.1993.tb06942.x",

language = "English (US)",

volume = "41",

pages = "367--370",

journal = "Journal of the American Geriatrics Society",

issn = "0002-8614",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type

T2 - Preliminary Results

AU - Burke, William J.

AU - Ranno, Anthony E.

AU - Roccaforte, W. H.

AU - Wengel, Steven P.

AU - Bayer, Barbara L.

AU - Willcockson, Nancy K.

PY - 1993/4

Y1 - 1993/4

N2 - Objective: To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion: L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT. 1993 The American Geriatrics Society

AB - Objective: To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion: L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT. 1993 The American Geriatrics Society

UR - http://www.scopus.com/inward/record.url?scp=0027418345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027418345&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.1993.tb06942.x

DO - 10.1111/j.1532-5415.1993.tb06942.x

M3 - Article

C2 - 8463521

AN - SCOPUS:0027418345

VL - 41

SP - 367

EP - 370

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 4

ER -

L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this